ASX Share rice
Thu 13 May 2021 - 01:18:pm (Sydney)

OSP Share Price

OSPREY MEDICAL INCOSPHealth Care Equipment & Services

OSP Company Information

Name:

Osprey Medical, Inc

Sector:

Healthcare

Industry:

Medical Devices

Address:

5600 Rowland Road Minnetonka MN United States 55343

Phone:

952 955 8230

Pres, CEO & Exec. Director:

Mr. Michael McCormick

Co-Founder:

Dr. J. Edward Shapland

VP of Fin. & CFO:

Ms. Nancy Ness

VP of Operations & IT:

Mr. Vic Fabano

VP of Regulatory Affairs, Compliance & Quality:

Ms. Melanie Hess

VP of Marketing, Education & Reimbursement:

Mr. Doug Schoenberg

Company Sec.:

Mr. Brendan T. Case C.P.A., BEc, Grad Dip., MComLaw, CPA, Dip FP

Company Overview:

Osprey Medical, Inc., a commercial stage company, provides contrast reduction and monitoring technologies in the United States and internationally. It offers AVERT, AVERT Plus, DyeVert NG, DyeVert Plus System, and DyeVert Plus EZ Systems, which are used to protect patients from the harmful effects of X-ray dye used during commonly performed angiographic imaging procedures. The company was incorporated in 2005 and is headquartered in Minnetonka, Minnesota.

OSP Share Price Information

Shares Issued:

5.13B

Market Capitalisation:

$82.10M

Revenue (TTM):

$1.67M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.045

Operating Margin (TTM):

$-8.01

Return On Assets (TTM):

$-0.89

Return On Equity (TTM):

$-2.15

Quarterly Revenue Growth (YOY):

-0.531

Gross Profit(TTM):

$448.18K

Diluted Earnings Per Share (TTM):

$-0.014

OSP CashFlow Statement

CashFlow Date:

2020-12-31

Investments:

$-341,094.52

Change To Liabilities:

$-272,355

Total Cashflow From Investing Activities:

$-262,711

Net Borrowings:

$1.33M

Net Income:

$-13,378,070

Total Cash From Operating Activities:

$-12,707,135

Depreciation:

$301.68K

Change To Inventory:

$6.99K

Change To Account Receivables:

$141.86K

Sale Purchase Of Stock:

$9.16M

Capital Expenditures:

$262.71K

OSP Income Statement

Income Date:

2020-12-31

Income Before Tax:

$-17,362,753.83

Net Income:

$-17,369,605.30

Gross Profit:

$581.90K

Operating Income:

$-17,383,575.69

Income Tax Expense:

$5.28K

Total Revenue:

$2.17M

Cost Of Revenue:

$1.59M

OSP Balance Sheet

Balance Sheet Date:

2020-12-31

Intangible Assets:

$75.71K

Total Liabilities:

$4.54M

Total Stockholder Equity:

$5.71M

Other Current Liabilities:

$1.97M

Total Assets:

$10.24M

Common Stock:

$81.17K

Retained Earnings:

$-128,213,342

Other Assets:

$12.25K

Cash:

$7.51M

Total Current Liabilities:

$3.26M

Short-Term Debt:

$1.33M

Property - Plant & Equipment:

$890.79K

Net Tangible Assets:

$4.34M

Total Current Assets:

$6.93M

Net Receivables:

$183.04K

Short-Term Investments:

$1.25M

Inventory:

$827.04K

Accounts Payable:

$821.95K

Non Currrent Assets (Other):

$15.90K

Short-Term Investments:

$1.25

Non Current Liabilities Total:

$307.11K

OSP Share Price History

OSP News

13 Jan, 2021
For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...
08 Dec, 2020
Peter Bender is the CEO of Huon Aquaculture Group Limited ( ASX:HUO ), and in this article, we analyze the executive's...
02 Nov, 2020
In this article we are going to estimate the intrinsic value of Huon Aquaculture Group Limited (ASX:HUO) by taking the...
12 Oct, 2020
We feel now is a pretty good time to analyse Osprey Medical, Inc.'s (ASX:OSP) business as it appears the company may...
29 Sep, 2020
Osprey Medical, Inc. (ASX:OSP) (Osprey or the Company) is pleased to announce that the Company is a winner of the prestigious Supplier Horizon Award from Premier Inc., one of the leading Group Purchasing Organisations (GPOs) in the US with over 4,100 member hospitals in its network.
13 Aug, 2020
Osprey Medical, Inc. (ASX:OSP) (Osprey or the Company) is pleased to announce that the Company has received CE Marking for the DyeVert Power XT 2nd generation device.
30 Jul, 2020
GE Healthcare and Osprey Medical Inc. (ASX:OSP) (Osprey) today announced a strategic alliance under which GE Healthcare will exclusively distribute Osprey’s product portfolio in Europe, Russia, Middle East, Africa, Central Asia and Turkey. Osprey’s DyeVert™ contrast minimization devices, complemented by GE Healthcare's range of iodinated x-ray contrast media, offer healthcare professionals a technology platform to address the rising problem of Acute Kidney Injury (AKI) following interventional coronary angiograms in patients with Chronic Kidney Disease (CKD).